Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.45 |
| ▸ | EML4 | Q9HC35 | 2/20 | 0.44 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.42 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20655389 | 0.91 | EGFR (0.45) | EGFRERBB2IGF1R | |
| SCHEMBL19089532 | 0.88 | EGFR (0.46) | EGFRERBB2IGF1RALKEML4 | |
| SCHEMBL19089297 | 0.87 | EGFR (0.53) | EGFRERBB2ERBB4 | |
| SCHEMBL19089290 | 0.85 | EGFR (0.66) | EGFRALKEML4 | |
| SCHEMBL19089365 | 0.80 | EGFR (0.49) | EGFRIGF1RALKEML4 | |
| SCHEMBL17385155 | 0.79 | EGFR (0.71) | EGFRERBB2ALKEML4ERBB3 | |
| SCHEMBL19089372 | 0.79 | EGFR (0.62) | EGFRERBB2ALKEML4 | |
| SCHEMBL20655613 | 0.78 | EGFR (0.58) | EGFRERBB2ALKEML4 | |
| SCHEMBL19089585 | 0.78 | EGFR (0.56) | EGFRERBB2 | |
| SCHEMBL19089597 | 0.78 | EGFR (0.63) | EGFRERBB2IGF1RALKEML4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10342796-B2 | Acrylanilide derivative, preparation method, and applications thereof in pharmacy | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-07-09 | — | — | US | disclosed |
| US-20190015413-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD, AND APPLICATIONS THEREOF IN PHARMACY | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-01-17 | — | — | US | disclosed |
| WO-2017114500-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN PHARMACY | 恩瑞生物医药科技（上海）有限公司 | 2017-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10342796-B2 | Acrylanilide derivative, preparation method, and applications thereof in pharmacy | EGFR, ABL1, CSNK1A1 | EGFR 1/4885ERBB2 4/4885IGF1R 619/4885 |
| US-20190015413-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD, AND APPLICATIONS THEREOF IN PHARMACY | EGFR, ABL1, CSNK1A1 | EGFR 1/4885ERBB2 4/4885IGF1R 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.